Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-03-04

Clinical Trial Update: Transition From Alendronate to Romosozumab (AMG 785) [Phase 1]

View source ↗

Summary

Phase 1 trial update describing transition from alendronate to romosozumab (AMG 785) in osteoporosis; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Romosozumab (romosozumab)
  • alendronate (alendronate)

Snippet

Sponsor: Amgen | Conditions: Osteoporosis | Phase 1 | Status: COMPLETED | Results posted: 2019-03-04